Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Early Pipeline Case Study

- PMLiVE

Cancer Research UK and Teon Therapeutics announce treatment of first patient in phase 1/2 trial for difficult-to-treat cancers

The trial is currently open to recruitment at The Royal Marsden and additional sites are anticipated to open shortly

- PMLiVE

Motor Neurone Disease Association and tech innovators collaborate to produce I Will Always Be Me

The book, the first of its kind, is for people living with MND and banks their voices as they read aloud

- PMLiVE

International Women’s Day 2022

This year the theme of International Women’s Day is ‘break the bias’, focussing on how our actions in our communities, workplaces, schools and universities can unite our individual actions with...

Mednet

How I’m helping to #BreakTheBias: International Women’s Day

What do you think of when you imagine a scientist? Who do you see in a lab coat? Gender stereotypes and assumptions are rife and, as a child, the thought...

Lucid Group Communications Limited

How do doctors want to engage with pharma on new products?

More than 80% of European doctors agree they are interested in staying up-to-date with new developments about pharmaceutical products. But what influences their choice of treatment and how do they...

M3 (EU)

Virtual collaboration tools to reduce “digital overload”

Considering its impact on our health and productivity, digital overload is clearly something that we need to take seriously.

Impetus Digital

- PMLiVE

FDA approves BMS’ Opdivo with chemotherapy for certain lung cancer patients

This is the first and only immunotherapy-based treatment approved for use before surgery for patients with non-small cell lung cancer

- PMLiVE

bluebird bio shares therapy updates for 2022

The company provided information for its first two gene therapies and its lovo-cel BLA submission for sickle cell disease

Extraordinary lives: advancing change in rare diseases

Rare Disease Day is all about raising awareness and generating change for the 300 million people worldwide living with a rare disease. On this day across the globe, the rare...

Lucid Group Communications Limited

Extraordinary lives: advancing change in rare diseases

We are extending the conversation for Rare Disease Day by continuing to raise awareness and generate change for the 300 million people worldwide living with a rare disease, their families...

Lucid Group Communications Limited

- PMLiVE

Results from trial show Eli Lilly’s COVID-19 drug improves survival rates

The RECOVERY trial is the biggest study of COVID-19 treatments in the world, involving more than 47,000 participants in the UK

- PMLiVE

UK government announce £260m to boost healthcare research and manufacturing

This investment will help the NHS deliver new life-saving treatments to patients more efficiently and will help to support more diverse and inclusive clinical research

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links